ERBB2 and adenocarcinoma: Adenocarcinoma cases had a higher prevalence of SNVs, CNVs, and/or fusions/rearrangements in 28 genes including therapy-associated genes such as KRAS (37.5% vs 4.6%), EGFR (17.1% vs 1.3%), BRAF (5.2% vs 1%), ERBB2 (1.8% vs 0.8%), RET (0.9% vs 0.3%), and ROS1 (1.2% vs 0.1%) (Figure 1B; Supplementary Table S1).